PANTOPRAZOLE SODIUM HYDRATE

5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; Pantoprazolum; Pantoprazole sodium sesquihydrate, Pantozol sesquihydrate, Protonix sesquihydrate;

PANTOPRAZOLE

 

PRODUCT IDENTIFICATION

CAS RN

102625-70-7 (parent), 138786-67-1 (sodium), 164579-32-2 (Sodium hydrate)

EINECS RN

 

FORMULA

C16H14F2N3O4SNa·1/2H2O

MOLE WEIGHT

405.35 (anhydrous basis)

CHEMICAL FAMLY

Benzimidazole

CATEGORY

Anti-ulcerative

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

white to off-white crystalline powder

MELTING POINT

139 - 140 C

BOILING POINT

 

DENSITY

 

SOLUBILITY IN WATER

Miscible (Very soluble in phosphate buffer at pH 7.4; practically insoluble in n-hexane)

pH

9.9 - 11 (2% solution)

VAPOR DENSITY

 

REFRACTIVE INDEX

 

FLASH POINT

 

 

STABILITY AND REACTIVITY
STABILITY Stable under normal conditions.

INCOMPATIBILITIES

Oxidizing agents
DECOMPOSITION
PRODUCTS

 

POLYMERIZATION Has not been reported

TOXICOLOGICAL NOTE

Oral rat LD50: 747 mg/kg

 

SAFETY NOTES

HAZARD OVERVIEW

Harmful if swallowed. May cause long-term adverse effects in the aquatic environment.

EYE

May cause eye irritation

SKIN

May cause skin irritation. May be harmful if absorbed through skin.

INGESTION

Harmful if swallowed.

INHALATION

May be harmful if inhaled. May cause respiratory tract irritation.

CHRONIC

Possible hypersensitization.

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

 

HAZARD CLASS

 

PACKING GROUP

 

HAZARD SYMBOL

 

RISK PHRASES

 

SAFETY PHRASES

 

 

GENERAL DESCRIPTION & EXTERNAL LINKS

Wikipedia Linking: http://en.wikipedia.org/wiki/Pantoprazole

Pantoprazole’s labeled indication is for the short-term treatment (no more than 16 weeks) of erosive esophagitis associated with gastroesophageal reflux disease (GERD). It may also show benefit for the maintenance treatment of erosive esophagitis, the treatment of duodenal and gastric ulcers, the prevention of gastro-duodenal damage in patients taking NSAIDs, and as adjunctive therapy with antibiotics for the eradication of Helicobacter pylori. Intravenous pantoprazole is indicated for the short-term treatment (7-10 days) of GERD, as an alternative for those patients who are unable to take the oral formulation. Other potential uses for intravenous pantoprazole include prevention of aspiration pneumonia in patients undergoing surgery, prevention of stress ulcers in intensive care patients, treatment of pyloric channel ulcers, and treatment of Zollinger-Ellison syndrome. (http://www.hsc.wvu.edu/)

Metabolism: Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. CYP2C19 displays a known genetic polymorphism due to its deficiency in some sub-populations (e.g. 3% of Caucasians and African-Americans and 17-23% of Asians). Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values of 3.5 to 10.0 hours, they still have minimal accumulation (≤ 23%) with once daily dosing. (http://www.accessdata.fda.gov/)

An analogue to omeprazole, used in the treatment of erosive esophagitis associated with gastroesophageal reflux disease, administered orally or intravenously, and of pathological hypersecretion associated with Zollinger-Ellison syndrome or other neoplastic conditions, administered intravenously.

 

SALES SPECIFICATION

APPEARANCE

white to off-white crystalline powder

ASSAY

98.0 - 102.0%

MELTING POINT

139 - 140 C

WATER

4.0% - 6.0%

RELATED SUBSTANCE

1.0% max

pH

9.5 - 11

HEAVY METALS

10ppm max

 

PACKING

 

 

PRICE

Click to open the table

 

Click to close the table